Results 201 to 210 of about 46,257 (309)

The Spectrum of Abnormal Tongue Movements: Review of Phenomenology, Etiology, and Differential Diagnosis

Movement Disorders Clinical Practice, EarlyView.
ABSTRACT Background Classifying abnormal tongue movements is challenging due to their varied presentations and limited visibility compared to other body parts. Accurate identification of the phenomenology guides physical examination and can point to specific diagnoses.
Nathaniel Bendahan, Seyed‐Mohammad Fereshtehnejad, Christos Ganos, Emily Swinkin, Anthony E. Lang   +4 more
wiley   +1 more source

Reversal of neuromuscular blockade with sugammadex based on the residual amount of rocuronium in the body using pharmacokinetic simulation: A single-centre observational study. [PDF]

Eur J Anaesthesiol
Morita T, Uchida O, Shibuta S, Hagihira S, Fujino Y.   +4 more
europepmc   +1 more source

The influence of mild hypothermia on reversal of rocuronium-induced deep neuromuscular block with sugammadex [PDF]

, 2015

core   +1 more source

Voice and Speech in Atypical Parkinsonian Disorders

Movement Disorders Clinical Practice, EarlyView.
Background Motor speech disorders are early, common, and functionally limiting features of atypical parkinsonian disorders (APDs) such as progressive supranuclear palsy (PSP), corticobasal syndrome (CBS), and multiple system atrophy (MSA). These impairments are underrecognized and undertreated in neurology clinics.
Federico Rodriguez‐Porcel, Farwa Ali, Michiko Bruno, Heather Davis Cuevas, Rohit Dhall, Kylie Dunne‐Platero, Lawrence I. Golbe, Ihtsham Haq, Nicole Herndon, Lawrence S. Honig, Kyurim Kang, Sarah Kremen, Guillaume Lamotte, Nikolaus R. McFarland, Michela Mir, Leila Montaser‐Kouhsari, Alexander Pantelyat, Joel Page, Hylan Pickett, Laura Purcell Verdun, Kelly Richardson, Jessica Shurer, Michelle Troche, Rene L. Utianski, Katya Villarreal‐Cavazos, Tuhin Virmani, Anne‐Marie Wills, as the Diagnosis and Treatment Working Group, CurePSP Center of Care (CoC) Network, Farwa Ali, Michiko Bruno, Timothy Chang, Rohit Dhall, Kimiko Domoto‐Reilly, Lawrence I. Golbe, Ihtsham Haq, Lawrence S. Honig, Sarah Kremen, Guillaume Lamotte, Zoltan Mari, Nikolaus R. McFarland, Leila Montaser‐Kouhsari, Alexander Pantelyat, Federico Rodriguez‐Porcel, Junaid Siddiqui, Jessica Shurer, Christopher Spears, Tuhin Virmani, Anne‐Marie Wills   +48 more
wiley   +1 more source

Prolonged neuromuscular blockade by non-depolarizing neuromuscular blocking agents

JA Clinical Reports, 2019
Michiko Higashi, Takahiro Tamura, Yushi U. Adachi   +2 more
doaj   +1 more source

Neuromuscular Blocking Agents and Reversal Agents Usage, and Neuromuscular Blockade Monitoring in the Intensive Care Unit - Review Article. [PDF]

Int J Gen Med
Szewczyk M, Bieniecka A, Sobolewski K, Banasiak Ł, Grabarczyk Ł.   +4 more
europepmc   +1 more source

Experience Using Efgartigimod to Treat Juvenile Myasthenia Gravis in China: A Multicenter Retrospective Study

Muscle &Nerve, EarlyView.
ABSTRACT Introduction/Aims Current therapeutic management of juvenile myasthenia gravis (JMG) predominantly relies on conventional immunosuppressive therapies and expert consensus extrapolated from adult data, creating a critical gap in high‐quality, pediatric‐specific clinical evidence.
Jing Lin, Guoyan Qi, Susan Luo, Qilong Jiang, Bitao Bu, Min Liu, Yuzhen Wei, Meigui Han, Junhong Yang, Zhilan Zhao, Lili Zhang, Yifan Zhang, Haoyou Xu, Xingjie Hao, Zhijun Li   +14 more
wiley   +1 more source

Neuromuscular blockade monitoring in pediatric patients. [PDF]

Anesth Pain Med (Seoul)
Ozgen ZSU.
europepmc   +1 more source

Biogenesis of Organelles and Membrane Proteins. [PDF]

, 1988
Harmey, Matthew A., Neupert, Walter, Nicholson, Donald W., Stuart, Rosemary A.   +3 more
core   +1 more source

Comorbidities and Treatment Patterns in People With Myasthenia Gravis in Denmark, Finland and Sweden: A Population‐Based Observational Study

Muscle &Nerve, EarlyView.
ABSTRACT Introduction/Aims Comorbidities are frequent in myasthenia gravis (MG) and may affect treatment choices. Conversely, MG treatments may impact the risk of comorbidity. Our objective was to examine comorbidity and MG treatment patterns in nationwide MG cohorts in Denmark, Finland, and Sweden. Methods We included individuals with ≥ 2 MG diagnoses
Sari Atula, Fredrik Piehl, Ingrid Schager, Fredrik Berggren, Karin Humle, Mari Savolainen, Didier Pitsi, Juha Mehtälä, Aino Vesikansa, Riina‐Minna Väänänen, Tero Ylisaukko‐oja, John Vissing   +11 more
wiley   +1 more source